Skip to main content
SpringerLink
Log in

Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The steady-state intravenous pharmacokinetics of pirenzepine has been investigated in 57 subjects whose renal function ranged from normal to chronic failure requiring regular haemodialysis.

Pirenzepine renal clearance, total clearance and terminal (dominant) half-life were found to be correlated with the creatinine clearance (CLCR), but this was not the case for the volume of distribution and the nonrenal clearance. The therapeutic regimen was well tolerated by all subjects. Haemodialysis did not significantly contribute to the elimination of pirenzepine. Dosage adjustment need only be considered in patients with CLCR<25 ml/min in order to reduce the frequency of minor side-effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carmine AA, Brogden RN (1985) Pirenzepine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30: 85–126

    Google Scholar 

  2. Ventkateswaran PS, Jeffers A, Hocken AG (1972) Gastric acid secretion in chronic renal failure. Br Med J 4: 22–23

    Google Scholar 

  3. Shepherd AMN, Stewart WK, Wormsley KG (1973) Peptic ulceration in chronic renal failure. Lancet 1: 1357–1359

    Google Scholar 

  4. Hammer R, Bozler G, Zimmer A, Koss FW (1977) Pharmakokinetik und Metabolismus von L-S 519 CL2 (Pirenzepin) beim Menschen. Therapiewoche 27: 1575–1593

    Google Scholar 

  5. Tanswell P, Kasper W, Zahn G (1986) Automated monoclonal radioimmunoassays for pirenzepine, a selective muscarinic receptor antagonist, in plasma and urine. J Immunol Methods 93: 247–258

    Google Scholar 

  6. Heinzel G (1982). In: Bozler G, van Rossum SM (eds) Pharmacokinetics during drug development. Springer, New York, pp 207–208

    Google Scholar 

  7. Londong W, Londong V, Tanswell P, Voderholzer U (1985) A pharmacokinetic study of the efficacy of pirenzepine after several days of treatment. Klin Wochenschr 63 [Suppl 4]: 168

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, Krankenhaus Merheim, Städtische Krankenanstalten Köln, Germany

    B. Krakamp & H. Vogel

  2. Department of Biochemistry, Dr. Karl Thomae GmbH, Biberach an der Riss, Germany

    P. Tanswell & G. Bozler

Authors
  1. B. Krakamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Tanswell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Bozler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krakamp, B., Tanswell, P., Vogel, H. et al. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. Eur J Clin Pharmacol 36, 75–78 (1989). https://doi.org/10.1007/BF00561028

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561028

Key words

Search

Navigation